[Therapeutic Drug Monitoring of Clozapine].

Z. Djerada,Françoise Daviet,P. Llorca,A. Eschalier,F. Saint-marcoux,D. Bentué‐Ferrer,F. Libert
Abstract:Clozapine is a prototypical atypical antipsychotic used to treat severe schizophrenia and for which a therapeutic drug monitoring (TDM) is quite commonly proposed. Clozapine is rapidly absorbed (maximum concentration reached within 1 to 4 hours), and is extensively metabolized in the liver by CYP1A2 to an active metabolite (and to a lesser extent, to inactive metabolites via other enzymes). Its half-life is 8 to 16 h. A therapeutic range has been proposed for clozapine as some studies have reported both a relationship between low plasmatic concentrations and resistance to treatment (threshold level is likely between 250 and 400 µg/L), and a relationship between high plasmatic concentrations and an increase in the occurrence of toxicity (alert level=1 000µg/L). Given the data obtained in different studies, the TDM was evaluated for this molecule, to: recommended.
What problem does this paper attempt to address?